NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due […]
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue guidance of $3.1 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Exact Sciences has helped increase colorectal cancer detection. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method.
Investors are bullish on this AI defense contractor. The numbers tell a different story.
Brookfield Renewable is always looking for opportunities to grow value for its shareholders. It's seeing a widening disconnect between public and private market values for renewable energy assets. Brookfield is capitalizing on this opportunity through its smart capital recycling strategy.
Exact Sciences ends the first quarter of 2025 on a solid note.
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 43.24% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RGNX
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses.
We recently published a list of the 30 Stocks That Should Double in 3 Years. In this article, we are going to take a look at where The Trade Desk, Inc. (NASDAQ:TTD) stands against other stocks that should double in 3 years. On April 25, Kari Firestone, Aureus Asset Management executive chairman and co-founder, joined […]
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CERT
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: REGN
We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against Billionaire George Soros’ other small-cap stocks with huge upside potential. When a legendary investor like George Soros makes a move, Wall […]
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Mentions: HRTX
Patients who test positive for circulating tumor DNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results, the company said.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.